BTCC / BTCC Square / Global Cryptocurrency /
Novo Nordisk Cuts Jobs and Lowers Forecast Amid Sales Slowdown

Novo Nordisk Cuts Jobs and Lowers Forecast Amid Sales Slowdown

Published:
2025-11-05 11:47:02
11
3
BTCCSquare news:

Novo Nordisk slashed its 2025 profit growth forecast to 4-7% from 4-10%, with sales growth projections trimmed to 8-11% from 8-14%. The Danish drugmaker will eliminate 9,000 jobs globally—5,000 in Denmark alone—as part of a restructuring plan.

Third-quarter operating profit plunged 30% to DKK 23.7 billion, missing analyst estimates. Wegovy sales grew 18% to DKK 20.4 billion but fell short of expectations. CEO Mike Doustdar cited slowing demand for GLP-1 treatments as the primary driver for reduced guidance.

The stock has halved year-to-date amid intensifying competition from Eli Lilly and generic copycats. Novo's challenges highlight shifting dynamics in the weight-loss drug market, where pricing pressure and saturation risks loom.

|Square

Get the BTCC app to start your crypto journey

Get started today Scan to join our 100M+ users

All articles reposted on this platform are sourced from public networks and are intended solely for the purpose of disseminating industry information. They do not represent any official stance of BTCC. All intellectual property rights belong to their original authors. If you believe any content infringes upon your rights or is suspected of copyright violation, please contact us at [email protected]. We will address the matter promptly and in accordance with applicable laws.BTCC makes no explicit or implied warranties regarding the accuracy, timeliness, or completeness of the republished information and assumes no direct or indirect liability for any consequences arising from reliance on such content. All materials are provided for industry research reference only and shall not be construed as investment, legal, or business advice. BTCC bears no legal responsibility for any actions taken based on the content provided herein.